Skip to main content

Advertisement

SpringerLink
Log in

Neuromyelitis optica

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Neuromyelitis optica (NMO, Devic’s syndrome) is characterized by concurrence of optic neuritis and transverse myelitis, typically associated with a lesion in the spinal cord extending over three or more vertebral segments. It is an inflammatory, demyelinating central nervous system disorder, and although it is most commonly relapsing, it is distinct from multiple sclerosis in that it is more severe, tends to spare the brain, and is associated with a longitudinally extensive lesion on spinal cord MRI. Furthermore, NMO is associated with a highly specific serum autoantibody marker, NMO-IgG, which targets the water channel aquaporin-4. The disease follows a relapsing course in more than 90% of patients. The relapses account for almost all disability associated with the disease because a secondary progressive course is uncommon, in contrast to multiple sclerosis. We recommend intravenous corticosteroids for acute myelitis and optic neuritis relapses, followed quickly by rescue plasmapheresis for severe, progressive, steroid-refractory events. Overwhelming evidence supports humoral autoimmune mechanisms in the pathogenesis of NMO, and most available data suggest that systemic immunosuppression is required to prevent attacks. We recommend long-term treatment with oral agents such as azathioprine or mycophenolate mofetil for patients with relatively mild disease and rituximab for those with more severe, recent attacks or treatment-refractory disease. We also recommend immunosuppression for at least 5 years in NMO-IgG seropositive patients presenting with a first-ever attack of longitudinally extensive transverse myelitis because they are at high risk for relapse or conversion to NMO.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al.: The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:810–815.

    Google Scholar 

  2. Wingerchuk DM, Weinshenker BG: Neuromyelitis optica. Curr Treat Options Neurol 2005, 7:173–182.

    Article  PubMed  Google Scholar 

  3. Wingerchuk DM, Lennon VA, Pittock SJ, et al.: Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485–1489.

    Article  PubMed  CAS  Google Scholar 

  4. Saiz A, Zuliani L, Blanco Y, et al., for the Spanish-Italian NMO Study Group: Revised diagnostic criteria for neuromyelitis optica (NMO): application in a series of suspected patients. J Neurol 2007 [Epub ahead of print].

  5. Lennon VA, Wingerchuk DM, Kryzer TJ, et al.: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106–2112.

    Article  PubMed  CAS  Google Scholar 

  6. Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473–477.

    Article  PubMed  CAS  Google Scholar 

  7. Jarius S, Franciotta D, Bergamaschi R, et al.: NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007, 68:1076–1077.

    Article  PubMed  CAS  Google Scholar 

  8. Matsuoka T, Matsushita T, Kawano Y, et al.: Heterogeneity of aquaporin 4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007; 130:1206–1223.

    Article  PubMed  Google Scholar 

  9. Takahashi T, Fujihara K, Nakashima I, et al.: Anti-aquaporin 4 antibody is involved in the pathogenesis of NMO: a study on antibody titer. Brain 2007, 130:1235–1243.

    Article  PubMed  Google Scholar 

  10. Pittock SJ, Lennon VA, Krecke K, et al.: Brain MRI abnormalities in neuromyelitis optica. Arch Neurol 2006, 63:390–396.

    Article  PubMed  Google Scholar 

  11. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al.: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63:964–968.

    Article  PubMed  Google Scholar 

  12. Lucchinetti CF, Mandler RN, McGavern D, et al.: A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002, 125:1450–1461.

    Article  PubMed  Google Scholar 

  13. Sinclair C, Kirk J, Herron B, et al.: Absence of aquaporin 4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal appearing white matter. Acta Neuropathol 2007, 113:187–194.

    Article  PubMed  CAS  Google Scholar 

  14. Roemer SF, Parisi JE, Lennon VA, et al.: Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194–1205.

    Article  PubMed  Google Scholar 

  15. Misu T, Fujihara K, Kakita A, et al.: Loss of aquaporin-4 in lesions in neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130:1224–1234.

    Article  PubMed  CAS  Google Scholar 

  16. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG: The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999, 53:1107–1114.

    PubMed  CAS  Google Scholar 

  17. Weinshenker BG, Wingerchuk DM, Vukusic S, et al.: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566–569.

    Article  PubMed  CAS  Google Scholar 

  18. Wingerchuk DM, Weinshenker BG: Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003, 60:848–853.

    PubMed  Google Scholar 

  19. Wingerchuk DM, Lennon VA, Pittock SJ, et al.: A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007, 68:603–605.

    Article  PubMed  CAS  Google Scholar 

  20. Filippini G, Brusaferri F, Sibley WA, et al.: Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000, CD001331.

  21. Beck RW, Cleary PA, Anderson MM Jr, et al.: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326:581–588.

    Article  PubMed  CAS  Google Scholar 

  22. The Optic Neuritis Study Group: Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997, 115:1545–1552.

    Google Scholar 

  23. Brusaferri F, Candelise L: Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000, 247:435–442.

    Article  PubMed  CAS  Google Scholar 

  24. Yan J, Richert JR, Sirdofsky MD: High-dose intravenous immunoglobulin for multiple sclerosis. Lancet 1990, 336:692.

    Article  PubMed  CAS  Google Scholar 

  25. Visser LH, Beekman R. Tijssen CC, et al.: A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004, 10:89–91.

    Article  PubMed  CAS  Google Scholar 

  26. Sorensen PS, Haas J, Sellebjerg F, et al.; TARIMS Study Group: IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004, 63:2028–2033.

    PubMed  CAS  Google Scholar 

  27. Nos C, Comabella M, Tintore M, et al.: High dose intravenous immunoglobulin does not improve abnormalities in the blood-brain barrier during acute relapse of multiple sclerosis. J Neurol Neurosurg Psychiatry 1996, 61:418–419.

    Article  PubMed  CAS  Google Scholar 

  28. Chrousos GA, Kattah JC, Beck RW, et al.: Side effects of glucocorticoid treatment: experience of the Optic Neuritis Treatment Trial. JAMA 1993, 269:2110–2112.

    Article  PubMed  CAS  Google Scholar 

  29. Saida T, Tashiro K, Itoyama Y, et al.: Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005, 64:621–630.

    PubMed  CAS  Google Scholar 

  30. Papeix C, Vidal JS, de Seze J, et al.: Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007, 13:256–259.

    Article  PubMed  CAS  Google Scholar 

  31. Warabi Y, Matsumoto Y, Hayashi H: Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007, 252:257–261.

    Article  CAS  Google Scholar 

  32. Mandler RN, Ahmed W, Dencoff JE: Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219–1220.

    PubMed  CAS  Google Scholar 

  33. Watanabe S, Misu T, Miyazawa I, et al.: Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007, 13:968–974.

    Article  PubMed  CAS  Google Scholar 

  34. Remuzzi G, Lesti M, Gotti E, et al.: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004, 364:503–512.

    Article  PubMed  CAS  Google Scholar 

  35. Cree BA, Lamb S, Morgan K, et al.: An open-label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270–1272.

    PubMed  CAS  Google Scholar 

  36. Jacob A, Weinshenker B, McLinskey N, et al.: Retrospective analysis of rituximab treatment of 24 cases of neuromyelitis optica [abstract]. Neurology 2007, 68(Suppl 1):A206.

    Google Scholar 

  37. Rituxan warning. FDA Consum 2007, 41(2):3.

  38. Bakker J, Metz L: Devic’s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004, 31:265–267.

    PubMed  Google Scholar 

  39. Hartung HP, Gonsette R, Konig N, et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet 2002, 360:2018–2025.

    Article  PubMed  Google Scholar 

  40. Goodin DS, Arnason BG, Coyle PK, et al.: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003, 61:1332–1338.

    PubMed  CAS  Google Scholar 

  41. WeinstockGuttman B, Ramanathan M, Lincoff N, et al.: Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006, 63:957–963.

    Article  Google Scholar 

  42. Minagar A, Sheremata WA: Treatment of Devic’s disease with methotrexate and prednisone. Intl J MS Care (Serial online) 2000, 2(4). Available at http://www.mscare.org/cmsc/images/pdf/ijmsc2000dec.pdf. Accessed Oct. 16, 2007.

  43. Weinshenker BG, O’Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878–886.

    Article  PubMed  CAS  Google Scholar 

  44. Keegan M, Pineda AA, McClelland RL, et al.: Plasma exchange for severe attacks of demyelination: predictors of response. Neurology 2001, 58:143–146.

    Google Scholar 

  45. Watanabe S, Nakashima I, Misu T, et al.: Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007, 13:128–132.

    Article  PubMed  CAS  Google Scholar 

  46. Ruprecht K, Klinker E, Dintelmann T, et al.: Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004, 63:1081–1083.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA

    Dean M. Wingerchuk

Authors
  1. Dean M. Wingerchuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian G. Weinshenker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean M. Wingerchuk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wingerchuk, D.M., Weinshenker, B.G. Neuromyelitis optica. Curr Treat Options Neurol 10, 55–66 (2008). https://doi.org/10.1007/s11940-008-0007-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-008-0007-z

Keywords

Search

Navigation